Multiple Myeloma- Prognostic Value of Circulating Plasma Cells (CPC)

Share Button

Circulating Plasma Cells (CPC) in Multiple Myeloma Patients at diagnosis indicate Cytogenetic Abnormalities as well as Poorer Overall Survival 

No one wants to hear the words “you have multiple myeloma.” However, while those two words indicate that you have an incurable blood cancer, with the sophisticated diagnostic testing available today, your prognosis can be from months to years or decades actually.

If you have been diagnosed with multiple myeloma it is important for you to know that there is a long and growing list of both conventional (FDA approved) and evidence-based, non-conventional therapies for you to use.

I am both a MM survivor and MM cancer coach. My intent is not to raise false hope by writing this blog post. Please understand that the average five-year survival rate today in 2017 is only 48%. But also understand that since my diagnosis in early 1994 I have known dozens of MMers who have lived 10,15, 20 years or more.

Image result for image of circulating plasma cells

The two articles linked and excerpted below discuss a prognostic indicator called circulating plasma cells (CPC). Your job as a newly diagnosed MMer is to learn as much as you possibly can about your diagnosis. The more you know about your MM now the better your decision-making will be about your therapies going forward.

Please scroll down the page, post a question or comment and I will reply to you ASAP.

Thanks and hang in there,

David Emerson

  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis

“The clinical significance and prognostic role of circulating plasma cells (CPCs) in multiple myeloma (MM) are still controversial…

11 studies covering a total of 2943 patients were included. Pooled hazard ratios (HRs) revealed that the presence of CPCs predicted aggressive disease progression

Conclusions– CPCs status is associated with poorer survival outcome in multiple myeloma. Additionally, increased ISS stage could be significant risk factors for the presence of CPCs.

Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era

“Patients with CPCs had a higher incidence of harboring high-risk cytogenetics by FISH compared with those without CPCs …

Among individual cytogenetic abnormalities, the frequency of t(4;14) was over twofold greater in patients with CPCs compared with those without…

The frequency of deletion 13q or monosomy 13 was also higher in the subgroup of patients with CPCs…

On comparing the pre-transplant response, the incidence of very good partial response (VGPR) or better at transplant was lower in patients with CPCs compared with those without…

Similarly, only 4.9% of patients with CPCs were in CR prior to transplant compared with 18.9% of patients without CPCs…

 

About

David Emerson is a 23 year Multiple Myeloma survivor. He started PeopleBeatingCancer.org as a non-profit in 2004 to help cancer survivors and caregivers navigate the vast world of cancer issues by providing evidence-based information on the most pressing cancer issues. Since 2004, David has impacted over 600,000 people through this website. He is in the process of developing cancer-specific coaching program, and also does one-on-one coaching via phone or email. Thank you for visiting!

Posted in Multiple Myeloma, Newly Diagnosed, non-conventional therapies Tagged with:

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You can take control of your Multiple Myeloma.

side-widget-mm-webinar-image